One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease
|4||Not yet recruiting||
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991
† Study has passed its completion date and status has not been verified in more than two years.